Home/Pipeline/Biosimilar Insulin Aspart

Biosimilar Insulin Aspart

Diabetes

Development / ANDA FiledActive

Key Facts

Indication

Diabetes

Phase

Development / ANDA Filed

Status

Active

Company

Amphastar Pharmaceuticals

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals' mission is to develop, manufacture, and market essential, high-barrier-to-entry pharmaceuticals, with a strategic focus on complex generics, proprietary products, and biosimilars. The company has achieved significant recognition, including an FDA Drug Shortage Assistance Award for its subsidiary, and commercial success with market-leading products like BAQSIMI® nasal glucagon. Its strategy leverages a fully integrated operational model, combining proprietary technology platforms in drug delivery with a diversified portfolio targeting endocrinology, pulmonology, and nephrology to drive sustainable growth.

View full company profile

Therapeutic Areas

Endocrinology Pulmonology Nephrology

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active